

In-Vitro Toxicology Testing Market to Reach \$27.38 billion with 14.10% CAGR Forecast to 2022

Toxicity Endpoints & Tests (Carcinogenicity, Dermal Toxicity, Genotoxicity), Technology (OMICS Technologies, Cell Cultu

PUNE, MAHARASHTRA, INDIA, September 12, 2016 /EINPresswire.com/ -- [In-Vitro Toxicology Testing](#) Industry

Description

Wiseguyreports.Com Adds “In-Vitro Toxicology Testing -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021” To Its Research Database

Global in-vitro toxicology testing market is expected to reach USD 27.38 billion by 2021 from USD 14.16 billion in 2016, growing at a CAGR of 14.10% for the next five years 2016-2021. In-vitro toxicology testing is the scientific analysis of toxic effects produced by chemical substances on cultured mammalian cells or bacteria. Toxicity testing is very essential in drug discovery as identifies the toxic effects of new compound in the early stages of drug discovery. This early detection of toxicity reduces the development cost and time.

Report Detail's @ <https://www.wiseguyreports.com/reports/635491-in-vitro-toxicology-testing-2016-to-2021>

Increasing technological advancements, rising research & development in cell culture, growing demand for in-vitro toxicology tests over the conventional in-vivo tests, increasing awareness towards toxicity testing studies, rising health-consciousness amongst individuals, growing economic status in emerging nations, existence of favorable regulatory authorities for toxicology testing using the in-vitro tests are driving the growth of in-vitro toxicology testing market. However, scarcity of in-vitro models to detect immunostimulation & autoimmunity, lack of predictive ability of in vitro testing over in vivo testing, technological disadvantages limiting the use & decreasing adoption rate are the major factors that restrain the growth of in-vitro toxicology testing market.

Global in-vitro toxicology testing market is segmented based on the product, type, toxicity endpoints & tests, technology, method, and industry. Based on product, the market is further sub-segmented as assays, reagent & labware, and service. Assays segment is estimated to command the largest share of global in-vitro toxicology testing market by product in 2016. Based on type, the market is segmented as ADME, dose, and toxic substance.

Request for Sample Report @ <https://www.wiseguyreports.com/sample-request/635491-in-vitro-toxicology-testing-2016-to-2021>

Toxicity endpoints & tests is further segmented as systemic toxicity, dermal toxicity, carcinogenicity,

ocular toxicity, skin sensitization & irritation, genotoxicity, neurotoxicity, and organ toxicity. Systemic toxicity is estimated to command the largest share of global in-vitro toxicology testing market by toxicity endpoints & tests in 2016. Technology is further segmented as OMICS technologies & cell culture technology.

By method, the market is segmented as in-silico method, biochemical assays, cellular assays, and ex vivo models. In-silico method is estimated to command the largest share of global in-vitro toxicology testing market by method in 2016. The market, by industry, is sub-segmented as cosmetics & household products, pharmaceutical, diagnostics, chemical, & food. The cosmetics & household products industry is estimated to account for the largest market share of global in-vitro toxicology testing market by industry in 2016.

On the basis of geographical region the global in-vitro toxicology testing market is segmented as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Europe is estimated to account for the largest share of 32.5% of the global in-vitro toxicology testing market in 2016, whereas Asia-Pacific is estimated to grow at the highest CAGR of 16.10% during the forecast period 2016-2021.

The key players in global in-vitro toxicology testing market include,

Covance, Inc. (A subsidiary of LabCorp) (U.S.), Agilent Technologies, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Eurofins Scientific SE (Luxembourg), General Electric Company (U.S.), BioReliance, Inc. (A subsidiary of Merck & Co, Inc.) (U.S.), Charles River Laboratories International, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Catalent (U.S.), and Cyprotex (U.K.), among others.

Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=635491

Table Of Content

1. Introduction
 - 1.1 Market Definition
 - 1.2 Study Deliverables
 - 1.3 Base Currency, Base Year and Forecast Periods
 - 1.4 General Study Assumptions
2. Research Methodology
 - 2.1 Introduction
 - 2.2 Research Phases
 - 2.2.1 Secondary Research
 - 2.2.2 Primary Research
 - 2.2.3 Econometric Modelling
 - 2.2.4 Expert Validation
 - 2.3 Analysis Design
 - 2.4 Study Timeline
3. Overview
 - 3.1 Executive Summary
 - 3.2 Key Inferences
 - 3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
 - 4.1 Market Drivers
 - 4.2 Market Restraints

- 4.3 Key Challenges
- 4.4 Current Opportunities in the Market
- 5. Market Segmentation
 - 5.1 Product
 - 5.1.1 Introduction
 - 5.1.2 Assays
 - 5.1.3 Reagents & Labware
 - 5.1.4 Services Growth Hormone Therapy

Continued...

Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.